Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary

August 3, 2023

OTC Pink Market US Health Care Biotechnology earnings 31 min

Earnings Call Speaker Segments

Brant Biehn

executive
#1

Good afternoon, everyone, and thanks for joining us on today's call. With us from Vaxart are our Chief Executive Officer, Andrei Floroiu; our Founder and Chief Scientific Officer, Dr. Sean Tucker; our Chief Medical Officer, Dr. James Cummings; and our Chief Financial Officer, Phil Lee. Before we get started, I want to remind all of you that on this conference call, Vaxart might make forward-looking statements. Those include statements regarding the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about clinical trials that are ongoing or planned. The outcomes we ultimately see may vary significantly from what's outlined in these forward-looking statements, due to several key considerations — among them the unpredictability that comes with clinical development and the regulatory pathway, plus additional risks laid out under the Risk Factors heading in Vaxart's latest Form 10-K annual report and in other periodic filings made with the SEC. Vaxart assumes no duty to revise any forward-looking statements following today's call. At this point I'll hand things over to Andrei Floroiu. Andrei?

Cezar Floroiu

executive
#2

Thank you, Brant, and thanks to each of you for being with us today. On this call, we'll go over the recent progress achieved in our norovirus oral pill vaccine program. We'll also preview the milestones still ahead of us for the back half of the year, and touch briefly on our COVID program, after which we'll take your questions. In the second quarter, we were glad to report positive preliminary top line results from our Phase II dose-ranging trial for the bivalent oral vaccine candidate, delivered within the timeline we had stated. James will walk through the data and explain what it means for this potentially groundbreaking vaccine. It's worth emphasizing that these data add to a growing body of evidence validating Vaxart's platform as a way to explore the possible benefits of mucosal vaccination. Oral vaccines are intended to elicit mucosal immunity. That is a highly important distinguishing characteristic of our platform. The clinical data generated so far across our many programs indicate that vaccination by this route may deliver several key benefits: broader cross-strain protection, less viral transmission, longer-lasting protection, and a wider immune response via activation of both serum and mucosal immunity. Another key distinguishing characteristic of our vaccines is the oral pill format. The possible benefits of oral pill vaccines are so fundamental that turning them into reality could transform how the world thinks about vaccines and vaccination. With oral pill vaccines, we could vaccinate far more people faster, with greater ease and without pain, compared with what we do now using injectable vaccines. This vision represents the future of vaccination, and we are working extremely hard to bring it about. Throughout Vaxart, we are enthusiastic about what our norovirus vaccine program could achieve. We think we hold the most advanced norovirus vaccine candidate in clinical development that is both formulated for oral administration and designed for delivery to the gastrointestinal system. Norovirus represents a major public health problem in developed countries, and no vaccine has been approved. Over 21 million people in the U.S. get infected annually, producing a yearly disease burden exceeding $10 billion in the U.S. alone. And this summer, the virus remains a leading topic of infectious disease coverage nationwide, as case counts have climbed to at least a 3-year high. We believe our norovirus vaccine program could address this need along with the substantial, tremendous disease burden that norovirus carries. Looking forward, we have 2 key clinical milestones this year, and we remain on track to reach both. First, we expect to report top line data from the ongoing Phase II Challenge Study of our GII norovirus vaccine candidate during the third quarter of this year. We also anticipate kicking off this year clinical trials funded by the Bill & Melinda Gates Foundation, which will assess whether our norovirus vaccine candidates can generate antibodies in breast milk and pass those antibodies along to young infants. Before handing things over to James, I'd like to give a quick update on our COVID program. Up to now, Vaxart's COVID-19 vaccine constructs have shown a favorable immune profile. Vaxart keeps moving forward with this program, and given the mucosal activity data observed across our existing constructs, we think there could be a route toward creating an oral beta coronavirus vaccine. We're evaluating what to do next and will share updates once they're ready. The White House recently introduced a new office of pandemic preparedness and response policy. The U.S. government's proactive stance on pandemic preparedness is very encouraging to us, and we strongly back worldwide efforts to stay ahead of the next global health crisis. While managing the post emergency phase of the pandemic, we need to establish stronger defenses against future infectious diseases and other threats. Vaxart holds the view that a cross protective vaccine might enhance our capacity to combat future pandemics, and we're dedicated to that work. As you can tell, we have strong faith in what our technology can achieve and its potential impact on global public health, and we're thrilled about the opportunities ahead. I'll now hand the call to James for a closer look at our norovirus program.

James Cummings

executive
#3

Thanks, Andrei. During Q2, we achieved meaningful clinical milestones, most notably the encouraging initial top-line findings we shared from the Phase II dose-ranging trial of our bivalent norovirus vaccine candidate. From what we've observed so far, we think these results are encouraging for this candidate and, on a wider scale, for our vaccine platform. Keep in mind that this candidate includes 2 genotypes, GII and GII.4, and together those have been responsible for most human norovirus illness over the last 20 years. As a reminder, 135 healthy adults were enrolled at 3 sites across the United States in this study. The initial 10 sentinel participants were given open-label high-dose vaccine, while the rest were randomly assigned to receive high-dose vaccine, low-dose vaccine, or placebo. There were 50 subjects in each of the double-blinded vaccine arms, and 25 subjects in the placebo arm. Safety and immunogenicity served as the primary endpoints, with the goal of establishing a dose level for Phase III development. Let's pause now to go over the results. As we laid out in detail in our July announcement, the trial's preliminary findings demonstrated strong serum immune responses at Day 29 compared with Day 1 across all doses. A comparable rise in serum antibody responses appeared with both vaccine doses, and no statistical difference was found between the medium and high dose arms. At day 29, the increases in serum IgA, serum IgG and BT50 for both the GII.4 and GII strains among the vaccine arms resembled those observed in earlier norovirus studies run by Vaxart. The findings further show that the bivalent norovirus vaccine candidate was well tolerated, with a favorable safety profile that included no vaccine-related serious adverse events, or SAEs, and no dose-limiting toxicity. For both doses, adverse event rates were comparable to placebo. I want to emphasize that these preliminary data covered serum responses. Data from mucosal and cell-based assays will come at a later date. Everything we learn from this bivalent study, along with what we anticipate from our ongoing norovirus challenge study, will help guide how we choose dosage levels for a larger Phase 2b study and might support an end of Phase II meeting with the U.S. FDA, possibly in 2024. I'll now move to the Phase 2 GII norovirus Challenge Study, which is evaluating the safety, immunogenicity and efficacy of our monovalent norovirus vaccine candidate. This study could also assist in identifying a correlate of protection linking immune responses to the vaccine with a lower risk of norovirus infection and/or acute gastroenteritis secondary to norovirus. Enrollment in this ongoing double-blinded study has now been completed, and we still expect to unwind the study and report top line data during the current third quarter of 2023; we remain confident in the potential of our bivalent norovirus candidate as we move toward a BLA submission. We look forward to updating you on our progress in the coming months. At this point I'm going to pass things along to Phil Lee, who serves as our CFO, so he can walk through a short overview of our financial results. Phil?

Phil Eric Lee

executive
#4

Appreciate that, James. Today's press release lays out the specifics of how we did financially in Q2 of 2023. We brought in $1.4 million of revenue during that quarter, versus zero revenue for the same period in 2022. Most of that Q2 2023 revenue came from money we recognized for work done under the grant Vaxart received from the Bill & Melinda Gates Foundation. As of the close of 2023's second quarter, Vaxart held $67.9 million in cash, cash equivalents, restricted cash and marketable securities, down from $71.8 million on March 31, 2023. That drop stemmed mainly from cash spent on operations while we pushed our norovirus program forward, though it was partly offset by $13.6 million in net proceeds from a public offering we wrapped up in June 2023. Thanks to that offering, the company now expects its cash runway to stretch into the third quarter of 2024. Speaking for everyone at Vaxart, I want to express our gratitude for your time today; at this point we'll take your questions.

Charles Duncan

analyst
#5

You mentioned during your prepared comments that earlier in this quarter, preliminary top line results were released from the Phase II dose-ranging trial for the bivalent norovirus vaccine candidate. If you take the immunogenicity findings from that study and set them against what is seen following a natural infection with either strain, what's your level of satisfaction with those responses? Also, based on what the data shows, is there a need to adjust the dose downward or upward? Or do you think the current dose is the correct one?

James Cummings

executive
#6

I'll handle that question. Thank you. We're quite encouraged that, so far, results from this trial align with what earlier norovirus studies have shown. As you may remember, in the preliminary top line data we released during July, robust serum immune responses were demonstrated at Day 29 across every dose, compared with 21. Data from the mucosal assay and the cell-based assay are still pending; those will become available at a later point. After we've evaluated that information, I believe we'll be in a position to make a more definitive decision going forward.

Charles Duncan

analyst
#7

Okay, James. And what do you think about using just one dose rather than two for this program?

James Cummings

executive
#8

For adults, I'd say a single dose.

Charles Duncan

analyst
#9

OK. Then, heading into the third quarter, we expect to get results from the norovirus Town Study. I'm curious whether you could describe, maybe in qualitative terms instead of quantitative ones, the kinds of things you'd hope to observe that would give you encouragement and that you'd want to bring to the agency for the Phase II meeting.

James Cummings

executive
#10

I'd rather not forecast what the data will show before they're in hand. Of course, if things proceed as planned and match prior trials, and we observe strong signals from the mucosal or cell-based assays, that would be quite encouraging. Beyond that, we're eager for the findings we ought to report later during Q3 of this year regarding the noro-GII challenge. A decision will therefore take that into account too.

Charles Duncan

analyst
#11

All right. And for my final question, I realize you still need to hold your end of Phase II meeting, but what's your rough timeline for getting the next trial up and running? Also, do you envision Vaxart pushing this program ahead on its own, or are you considering adding a partner?

James Cummings

executive
#12

I'll handle the first part, and then I'll turn the second part over to Andrei, if that works. From where I sit, we want to review results from this trial, plus the 201 Challenge Study, prior to approaching the FDA. The next segment — a bigger trial — would move us toward a Phase 2b, which would move us toward end of Phase II talks with the FDA. As I said earlier, that might happen as early as 2024. Andrei, would you like to address the second part of that question?

Cezar Floroiu

executive
#13

Yeah, absolutely. Like our biggest rival in the norovirus area, <<inaudible>>, pointed out earlier in the year, late-stage vaccine assets — the norovirus programs, for instance — are of interest to a lot of big pharma companies and mid-sized ones too, and once we've got the data, we'll clearly be open to those conversations. And as you can imagine, there are pluses to both partnering and doing it on our own, and we're willing to look at the <<inaudible>> that creates the most value and gets the vaccine to patients faster.

Charles Duncan

analyst
#14

Okay, I'm eager to see the results from the Challenge Study.

Mayank Mamtani

analyst
#15

Regarding the monovalent Challenge Study specifically, from what I can gather, your pace of execution and enrollment has exceeded what you initially anticipated. So might you share insights gained from running that trial and the season during which these infections occur, and how might some of that be applied to further challenge study efforts, perhaps with your bivalent candidate or eventually the <<inaudible>> study? I'd appreciate hearing thoughts on that. Then, concerning the mucosal data you might report in addition to the dose-ranging bivalent results already shared from the university data, could you remind us what was observed with your earlier construct, so we can frame possible scenarios for what might appear on IDA? And when do you expect to present it? Is there a specific medical conference you have in mind? After that, I have a finance-related question.

James Cummings

executive
#16

Sure. I'll handle the first part, and Sean Tucker, our CSO, will address mucosal immunity since he's a leading global authority on it. As for takeaways from the Channel Study, such trials tend to be far more intense than what occurs naturally in real-world settings. This trial's sample size was designed mainly for descriptive statistical purposes, since our goal is grasping the actual mechanisms behind how this vaccine operates. To accomplish that, we're examining several measures, such as reduced severity of acute gastroenteritis from norovirus, less viral shedding, what influence or impact our vaccine might have on infectivity, and how it affects disease severity. All of these, in my view, matter greatly from a clinical or global health perspective. In addition, we're evaluating safety, immunogenicity, and the possibility of assessing what core immunity could be. For anyone on this call or listening, norovirus gastroenteritis has traditionally been regarded as appearing more seasonally. Thus, norovirus is generally more common, broadly speaking, in its seasonal pattern during winter. Even so, norovirus outbreaks do happen in essentially every month. You need only check the CDC's website in the United States, the WHO's quite comprehensive database, or the New York Times to see when outbreaks arise in places like nursing homes or on cruise ships. So while there is some seasonality in how norovirus traditionally spreads, it's a viral infection that affects individuals throughout the entire year. So given all that, I believe we'll consider running a Challenge down the road, if one becomes necessary — at the point when the Challenge model is ready and when we feel we've got the strongest shot at enrolling people to keep the study moving. Like you said, we're quite lucky to be pushing this study ahead and to get the data delivered on schedule. That has us pretty thrilled. On the mucosal immunity side, your question was specifically about — I believe the — what we're examining regarding mucosal immunity in the 202 study. And with the 202 study, mucosal immunity isn't available yet. That's still to come, correct? As for mucosal immunity from earlier work, I'd like to ask Dr. Sean Tucker whether you'd care to offer just a brief remark, since he was running that program back then. Sean?

Sean Tucker

executive
#17

Absolutely. Yeah, that's a fair thing to ask. So in the past, what we've shared is that a mucosal response is observed at roughly a 2 to tenfold rise when you're looking at fecal, or we've also discussed nasal responses, and you see a portion of participants responding at rates reaching above 90% when it comes to ASC count, or regarding the nasal response if we examine it very closely; therefore, what we anticipate is that GII will demonstrate a comparable mucosal response too.

Mayank Mamtani

analyst
#18

Understood. Thanks for that thorough and useful response. Now, regarding the extension of the financial runway that you pointed toward reaching in 3Q of next year — could you make clear what amount of additional nondilutive funding you are factoring in for that, whether it comes from the Melinda Gates Foundation or even any other types of government funding?

Cezar Floroiu

executive
#19

Phil, would you like to handle this one?

Phil Eric Lee

executive
#20

Absolutely. So when it comes to how far that runway now extends, what we're really going on is the plans we have in place today along with the grant we already hold from the Gates Foundation, correct? So, again, after we've looked at what comes out of the 201 study and worked out which direction that study should take, at that point we'll more or less settle on what happens next and any added spending that becomes necessary; as things stand, though, everything rests on the plans already in place and the grant already in hand, with nothing new on the grant side right now.

Mayank Mamtani

analyst
#21

All right, understood. We're eager to see the data from the Challenge Study soon.

Liang Cheng

analyst
#22

Liang Cheng here, filling in for Roger Song. Our initial question concerns the forthcoming Phase II ace 2 Challenging data. Could you provide some insight into what the go, no-go decisions would be for that Phase II Challenging data?

James Cummings

executive
#23

What I can offer is some insight rather than go, no-go — I believe that's something we'd need to discuss as a team. That said, we're certainly examining multiple endpoints and indicators. For instance, we're looking at a reduction in acute gastroenteritis severity. As I said earlier, a Challenge Study is extremely aggressive relative to what a person encounters in nature, so we aim to make sure that those who might become ill do become ill, correct? Still, we're seeking a reduction in acute gastroenteritis severity secondary to norovirus, possibly a reduction in shedding. In my view, shedding matters because it could serve somewhat as a surrogate — by reducing shedding, you'd reduce transmission, or you might. The impact on infectivity, I believe, will be extremely important, and once again I connect that to viral shedding. Then there's disease severity, correct? So just how sick are people actually becoming? I think we're examining each of those items, together with immunogenicity and safety, while also attempting to tease out, if possible, what a correlative immunity might look like. Those are the things we're taking into account as we review that data set.

Liang Cheng

analyst
#24

Absolutely, that's quite useful. Regarding the bigger Phase 2b trial, is there any direction available? And might you share some details about how the study is designed?

James Cummings

executive
#25

Of course. Let me offer a few perspectives. We'd examine the proof we're observing in the information coming out of both the 202 study we've been discussing — that information. A portion of it is already with us, though we're still awaiting the mucosal information plus what we learn regarding the effect from the 201 Challenge Study. By reviewing those two together, I believe we can figure out, or at least assist in figuring out, how large the trial could be. Among the elements that could influence that is whether a correlate can be identified, correct? If a correlate were available, that would allow for reducing the scale of — if not the Phase II, then certainly the Phase III. Therefore, the Phase 2b study would be bigger. You'd enroll a sufficient number of participants to guarantee a safety dataset that the FDA would find acceptable. And I don't really wish to talk with the FDA. Still, without question, it would exceed the size of the study we've just completed. And we'd be prepared to move forward as soon as that information is available and we've aligned internally. I trust that addresses your question.

Liang Cheng

analyst
#26

Understood. Excellent. Perhaps one more briefly to wrap up. Regarding the pivotal Phase III trial, I realize you likely lack extensive details. So which age groups would take priority, if you're able to address that?

James Cummings

executive
#27

Certainly. I'll address that specific point, and broadly regarding the Phase III. Once more, that Phase III hinges on findings from the GII Challenge Study, the Phase 2b trial, and our end of Phase II discussion with the FDA. We embrace the agency's direction sincerely, since all of us, I believe, want to deliver a remedy for something currently unanswered — namely, no vaccine has been approved for norovirus, correct? I believe we covered the schedule for the Phase III when we gain greater clarity guided by those milestones. As for our current position, within this trial we've evaluated the vaccine in those 18 and older, and I believe that's our aim as we proceed; however, that would hinge on — the Phase III design would hinge on discussions with the agency, the FDA.

Brant Biehn

executive
#28

Thank you so much. Alright, quite a few inquiries had come our way in advance through different platforms. Between Charles and Mayank, I believe nearly all of those have been addressed by now. So I'll go ahead — here's one I don't believe has been fully covered yet, James. This one is directed at you. Is there any quicker route toward commercialization that you can see, for instance an EUA or a reduced Phase III trial for norovirus, and what would be a realistic timeline to reach commercialization, James?

James Cummings

executive
#29

That's reasonable. Thank you, Brant. So we're still working through the possible paths forward and when commercialization might happen. But once those study results we're talking about right now give us a clearer picture, and depending on what those results and that data show along with our conversations with regulatory agencies, we'll figure out the optimal approach and schedule for bringing it to market.

Brant Biehn

executive
#30

That is great, James. And here's something else — I believe we didn't touch on it during this call, and James, this one is for you as well. Please walk us through again what you're seeking in the infant study and what it could mean for your norovirus program. James?

James Cummings

executive
#31

Alright, thanks. So how a vaccine might influence norovirus infectivity and transmission isn't known. Like I said, no vaccine for norovirus has been approved at this time. That said, certain research indicates that vaccinating kids could also lead to better health for grown-ups. You may not be able to prevent every case of illness, but we do understand that kids pick up the disease and can pass it to their families, so that's one aspect we're examining.

Brant Biehn

executive
#32

Alright, most of the remaining norovirus-related questions have already come up and been addressed by you, so I really appreciate that. I'd say investors and others on the call who still have questions are welcome to visit our fireside chat platform, which is located in the Investors section of our website, and they can post any additional questions there, and we will follow up during a fireside chat meeting soon and provide answers to those questions; so with that, we'll bring the meeting to a close. Thank you.

Operator

operator
#33

That brings an end to today's conference and webcast. At this point, you're free to disconnect your lines, and we appreciate your participation.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.